The cost of managing diabetes patients is extremely high, and many patients still experience poor glycemic control and renal complications, according to results of a study published online in the journal Diabetes Care.
The cost of managing diabetes patients is extremely high, and many patients still experience poor glycemic control and renal complications, according to results of a study published online in the journal Diabetes Care.
“The cost of caring for people with diabetes is substantial and is associated with suboptimal glycemic control, abnormal kidney function, and proteinuria,” wrote Fiona Clement, PhD, of the University of Calgary, in Calgary, Alberta, Canada, and colleagues.
The researchers compared laboratory-derived measures of glycemic control, the presence of renal complications, and the 5-year cost of caring for diabetes patients.
The authors identified 138,662 adults diagnosed diabetes as of May 1, 2004 to estimate a 5-year cost of care, which included physician visits, hospitalizations, ambulatory care, and drug costs. The researchers used linked laboratory and administrative clinical and costing data to determine the association between that 5-year cost and baseline glycemic control (HbA1c), proteinuria, and kidney function (eGFR).
The researchers determined the 5-year cost of care in Canadian dollars was $26,978 per patient, excluding drug costs. For patients 65 and older, the cost of care was $44,511, including drug costs. They noted that cost increased with worsening kidney function, presence of proteinuria, and suboptimal glycemic control (HbA1c >7.9%). Other characteristics that were linked with increasing cost included increasing age, Aboriginal status, socioeconomic status, duration of diabetes, and the presence of other illnesses.
“Future studies should assess if improvements in the management of diabetes, assessed with laboratory-derived measurements, result in cost reductions,” Dr Clement and colleagues concluded.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More